Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Equity Ratio (2020 - 2025)

Ovid Therapeutics' Equity Ratio history spans 6 years, with the latest figure at 0.87 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 16.94% year-over-year to 0.87; the TTM value through Dec 2025 reached 0.87, up 16.94%, while the annual FY2025 figure was 0.87, 16.94% up from the prior year.
  • Equity Ratio reached 0.87 in Q4 2025 per OVID's latest filing, up from 0.7 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.95 in Q3 2021 to a low of 0.59 in Q1 2024.
  • Average Equity Ratio over 5 years is 0.81, with a median of 0.83 recorded in 2023.
  • Peak YoY movement for Equity Ratio: skyrocketed 60.78% in 2021, then fell 29.5% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.92 in 2021, then fell by 7.79% to 0.85 in 2022, then dropped by 28.44% to 0.61 in 2023, then grew by 21.43% to 0.74 in 2024, then grew by 16.94% to 0.87 in 2025.
  • Per Business Quant, the three most recent readings for OVID's Equity Ratio are 0.87 (Q4 2025), 0.7 (Q3 2025), and 0.72 (Q2 2025).